SynthesisBMC cardiovascular disorders2026
The beneficial effects of Chlorella vulgaris supplementation on health-related indices in patients with non-alcoholic fatty liver disease: a GRADE-assessed systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Beneficial effects of Chlorella species supplementation in the general population: a GRADE-assessed systematic review and dose-response meta-analysis.Nutrition & diabetes · 2026Pooled it
- Review
- DoesFood science & nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis aimed to assess the impact of Chlorella vulgaris (C. vulgaris) consumption on cardiovascular disease risk factors in patients with non-alcoholic fatty liver disease (NAFLD). Relevant research was identified through electronic searches of databases up to September 19, 2025. Study quality was assessed using the Cochrane risk-of-bias tool (ROB 2). Seven trials, all conducted in Iran, with interventions ranging from 8 to 12 weeks and involving 375 participants, were included. C. vulgaris supplementation demonstrated significant reductions in weight (Weighted Mean Difference [WMD]= -1.62, 95% Confidence Interval [CI]: -2.24, -1.00), fasting blood sugar (FBS) (WMD= -6.25, 95% CI: -9.02, -3.47), high-sensitivity C-reactive protein (hs-CRP) (WMD= -1.02, 95% CI: -1.84, -0.19), low-density lipoprotein cholesterol (LDL-C) (WMD= -6.45, 95% CI: -12.25, -0.64), total cholesterol (TC) (WMD= -7.18, 95% CI: -10.84, -3.52), alkaline phosphatase (ALP) (WMD= -14.84, 95% CI: -27.81, -1.87), and aspartate aminotransferase (AST) (WMD= -4.99, 95% CI: -7.26, -2.71). This meta-analysis demonstrates that C. vulgaris supplementation significantly improves liver function, glycemic control, and lipid profiles in patients with NAFLD. However, all included studies were conducted in Iran, limiting the generalizability of these findings, and the certainty of evidence was rated as very low due to risk of bias, indicating that the results should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.